thumbnail image


  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • xLink BsAb platform
      • xLink MsAb platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
  • English
     
    • English
    • 中文


  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • xLink BsAb platform
      • xLink MsAb platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
  • English
     
    • English
    • 中文
  • xLinkBsAb

    Bispecific agonist antibody discovery platform

  • Via xLinkBsAb platform, we apply cross-linking dependency in developing anti-TNFRSF bispecific antibodies. Several IO or TA target dependent TNFRSF agonist antibodies have entered into the IND-enabling stage.

    LVGN5287

    xLinkBsAb checkpoint blocker and T cell activator

    Co-expression of PD-1 and CD137 on immune cells in tumors
    PD-1 blockade lead to increased expression of CD137
    PD-1 cross-linking dependent CD137 agonist activity
    Desirable drug-like properties

    LVGN5596

    xLinkBsAb tumor microenvironment immune activator

    B7H3 targeting highly pursued in the clinic
    B7H3-dependent activation of CD40 on APCs (i.e., DCs)
    Cross-presentation of tumor-derived antigens
    Priming of tumor-specific T cells
    Cross-linking dependent activity
    Desirable drug-like properties

    Lyvgen Biopharma engaged in development of innovative cancer treatment, is open to collaborate or out-license our pipelines or platform technology. Please contact us to explore collaboration opportunities.

    Contact us
沪公网安备 31011502015346号
|
沪ICP备20018873号-2
    Home
    About us
    xLinkAb
    Contact us
Lyvgen Biopharma Website 礼进生物 英文官网
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
https://user-assets.sxlcdn.com/images/676507/FiTA8WK-FQRyXrQDyd-HDkY3tpfI.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
Cookie的使用
我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
了解更多